CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Gilead exceeded market expectations in the second quarter, reporting earnings per share of $2.01 on revenue of $7.08 billion. Profitability metrics impressed with a 21.86% margin and a return on ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...